On Thursday, PepsiCo, Inc. (NYSE:PEP)’s shares inclined 0.10% to $96.63.
Mountain Dew, a product of Pepsico, Inc. (PEP) . Mountain Dew® and Doritos®, the ultimate fuel for gamers, are once again teaming up with Activision Publishing, Inc. for the latest installment in Call of Duty®, Black Ops III, which hits shelves worldwide on November 6. For the first time, the ‘Fuel Up for Battle’ program will offer fans exclusive Double XP in the highly-anticipated Call of Duty: Black Ops III Zombies mode, ‘Shadows of Evil.’
The Zombies mode in Black Ops III features its own XP progression system for fans – a first for the Call of Duty® franchise – adding greater depth and more re-playability to the Zombies gameplay that players have come to expect. Starting in early October, fans in the U.S. can collect codes from specially marked packages of DEW® and Doritos products to redeem points and earn up to 30 minutes of exclusive Zombies Double XP per day in addition to the chance to win other great prizes.
PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lay’s potato chips, Doritos tortilla chips, Cheetos cheese-flavored snacks, Tostitos tortilla chips, branded dips, Ruffles potato chips, Fritos corn chips, and Santitas tortilla chips. The company’s Quaker Foods North America segment provides Quaker oatmeal, grits, rice cakes, oat squares, and natural granola; and Aunt Jemima mixes and syrups, Quaker Chewy granola bars, Cap’n Crunch cereal, Life cereal, and Rice-A-Roni side dishes. Its Latin America Foods segment offers snack foods under the Doritos, Cheetos, Marias Gamesa, Ruffles, Emperador, Saladitas, Lay’s, Rosquinhas Mabel, Elma Chips, and Sabritas brands; and cereals and snacks under the Quaker brand.
People’s United Financial, Inc. (NASDAQ:PBCT)’s shares gained 0.62% to $16.14.
People’s United Financial, Inc. (PBCT) stated net income of $61.7 million, or $0.20 per share, for the second quarter of 2015, contrast to $72.3 million, or $0.24 per share, for the second quarter of 2014, and $59.2 million, or $0.20 per share, for the first quarter of 2015. Comprised of in the results for the second quarter of 2014 is a net after-tax gain of $13.4 million ($0.04 per share) resulting from the formation of a merchant services joint venture. Operating earnings were $63.7 million, or $0.21 per share, for the second quarter of 2015, contrast to $59.9 million, or $0.20 per share, for the second quarter of 2014, and $63.2 million, or $0.21 per share, for the first quarter of 2015.
The Company’s Board of Directors declared a $0.1675 per share quarterly dividend, payable August 15, 2015 to shareholders of record on August 1, 2015. Based on the closing stock price on July 15, 2015, the dividend yield on People’s United Financial common stock is 4.1 percent.
People’s United Financial, Inc. operates as the bank holding company for People’s United Bank that provides commercial banking, retail banking, and wealth administration services to individual, corporate, and municipal customers. The company operates through two segments, Commercial Banking and Retail Banking. The Commercial Banking segment principally comprises of commercial real estate lending, commercial and industrial lending, and commercial deposit gathering activities.
At the end of Thursday’s trade, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s shares surged 0.27% to $199.29.
Alexion Pharmaceuticals, Inc. (ALXN) declared financial results for the second quarter of 2015. Net product sales of Soliris® (eculizumab) grew to $636 million, a 24% enhance, contrast to $512.5 million for the same period in 2014, despite currency headwinds. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $1.44, contrast to $1.12 in the second quarter of 2014. On a GAAP basis, diluted EPS for the second quarter of 2015 was $0.83 per share, influenced by $40.1 million, or $0.20 per share, related to acquisition and restructuring costs resulting from the Synageva acquisition, contrast to $0.83 in the second quarter of 2014.
Second Quarter 2015 Financial Highlights
- Net product sales of Soliris®were $636 million contrast to $512.5 million in the same quarter last year.
- Non-GAAP R&D expense was $116.6 million contrast to $85.1 million in the same quarter last year. GAAP R&D expense was $131.7 million contrast to $92.6 million in the same quarter last year.
- Non-GAAP SG&A expense was $169.1 million contrast to $139.5 million in the same quarter last year. GAAP SG&A expense was $221.4 million contrast to $159.5 million in the same quarter last year.
- Non-GAAP effective tax rate was a benefit of 0.6% contrast to tax expense of 8.0% in the same quarter last year. In Q2 2015, the Company benefitted from the utilization of operating losses from Synageva in 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
Ambarella Inc (NASDAQ:AMBA), ended its Thursday’s trading session with -1.63% loss, and closed at $115.80.
Ambarella, Inc. (AMBA), a leading developer of video compression and image processing semiconductors, recently declared the acquisition of VisLab S.r.l., a privately held Italian company based in Parma, Italy for $30 million in cash. VisLab, the Vision and Intelligent Systems Laboratory at the University of Parma, is a pioneer in perception systems and autonomous vehicle research and was founded by Professor Alberto Broggi. The company has developed computer vision and intelligent control systems for automotive and other commercial applications, counting Advanced Driver Assistance Systems and several generations of autonomous vehicle driving systems. These comprise “Porter,” an autonomous vehicle that made a 13,000 km autonomous trip from Italy to China in 2010.
As part of the acquisition, VisLab’s 27 researchers will join Ambarella’s advanced computer vision development team. This will enable extensive and robust computer vision support in future Ambarella solutions targeting Ambarella’s core markets counting automotive, IP security, wearable, and flying cameras.
Ambarella, Inc. develops semiconductor processing solutions for video that enable high-definition (HD) video capture, sharing, and display worldwide. The company’s system-on-a-chip designs integrated HD video processing, image processing, audio processing, and system functions onto a single chip for delivering video and image quality, differentiated functionality, and low power consumption. Its solutions enable the creation of video content for wearable sports cameras, automotive aftermarket cameras, professional and consumer Internet Protocol (IP) security cameras, telepresence cameras, and unmanned aerial vehicles in the camera market; and manage IP video traffic, broadcast encoding and transcoding, and IP video delivery applications in the infrastructure market.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
